Lipodystrophies: Genetic and Acquired Body Fat Disorders
Top Cited Papers
- 1 November 2011
- journal article
- review article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (11), 3313-3325
- https://doi.org/10.1210/jc.2011-1159
Abstract
Context: Lipodystrophies are heterogeneous, genetic or acquired disorders characterized by selective loss of body fat and predisposition to insulin resistance. The extent of fat loss determines the severity of associated metabolic complications such as diabetes mellitus, hypertriglyceridemia, and hepatic steatosis. Evidence Acquisition and Synthesis: Both original and review articles were found via PubMed search reporting on clinical features and management of various types of lipodystrophies and were integrated with the author's knowledge of the field. Conclusion: The autosomal recessive congenital generalized lipodystrophy and autosomal dominant familial partial lipodystrophy (FPL) are the two most common types of genetic lipodystrophies. Mutations in AGPAT2, BSCL2, CAV1, and PTRF have been reported in congenital generalized lipodystrophy and in LMNA, PPARG, AKT2, and PLIN1 in FPL. CIDEC is the disease gene for autosomal recessive, FPL and LMNA and ZMPSTE24 for autosomal recessive, mandibuloacral dysplasia-associated lipodystrophy. Recently, an autosomal recessive autoinflammatory lipodystrophy syndrome was reported to be due to PSMB8 mutation. Molecular genetic bases of many rare forms of genetic lipodystrophies remain to be elucidated. The most prevalent subtype of acquired lipodystrophy currently occurs with prolonged duration of protease inhibitor-containing, highly-active antiretroviral therapy in HIV-infected patients. The acquired generalized and partial lipodystrophies are mainly autoimmune in origin and display complement abnormalities. Localized lipodystrophies occur due to drug or vaccine injections, pressure, panniculitis, and other unknown reasons. The current management includes cosmetic surgery and early identification and treatment of metabolic and other complications with diet, exercise, hypoglycemic drugs, and lipid-lowering agents.Keywords
Funding Information
- NIH
This publication has 97 references indexed in Scilit:
- PSMB8 Encoding the β5i Proteasome Subunit Is Mutated in Joint Contractures, Muscle Atrophy, Microcytic Anemia, and Panniculitis-Induced Lipodystrophy SyndromeAmerican Journal of Human Genetics, 2010
- Early onset mandibuloacral dysplasia due to compound heterozygous mutations in ZMPSTE24American Journal of Medical Genetics Part A, 2010
- Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutationsAmerican Journal of Medical Genetics Part A, 2010
- Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDECEMBO Molecular Medicine, 2009
- Lipodystrophies: Disorders of adipose tissue biologyBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- HIV-protease inhibitors block the enzymatic activity of purified Ste24pBiochemical and Biophysical Research Communications, 2008
- Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instabilityAmerican Journal of Medical Genetics Part A, 2008
- Phenotype and Course of Hutchinson–Gilford Progeria SyndromeThe New England Journal of Medicine, 2008
- The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphologyProceedings of the National Academy of Sciences of the United States of America, 2007
- Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophyMetabolism, 2007